Grants per year
Personal profile
Research Interests
I joined Northwestern University in August 2017 as a tenured Professor in Urology. I previously served as a Professor of Microbiology and Immunology at the Medical University of South Carolina and the University of Washington. I obtained a PhD from the University of British Columbia in Canada followed by post-doctoral training in Fred Hutchinson Cancer Research Center (FHCRC) and a faculty position at the University of Washington. My research focuses on understanding how cancer cells edit the immune system with the ultimate goal to develop effective immune therapy to control cancers.
Research in my laboratory include these specific aspects: 1) mechanisms of cancer immune evasion; 2) development of novel cancer immunotherapy; 3) Immune therapy-related mucosal toxicity; 4) mechanisms of cancer therapeutic resistance; 4) cancer biomarker discovery. Prostate Cancer is one of my lab's main focus areas. I am also researching the NKG2D axis in tumors which can be applied to a broad spectrum of cancer types and autoimmunity.
Training Experience
| 2002 | Postdoctoral Fellowship, Fred Hutchinson Cancer Research Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Genetics, University of British Columbia
… → 2000
MSc, Cell Biology, Peking University
… → 1991
Research interests
- Cancer Biology
- Immune Regulation
- Inflammation
- Inflammatory Bowel Disease
- Interdisciplinary Research
- Prostate Cancer
Fingerprint
Dive into the research topics where Jennifer Donglan Wu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Overcoming androgen receptor-mediated prostate cancer resistance to immunotherapy
U.S. Army Medical Research and Materiel Command
9/1/21 → 8/31/24
Project: Research project
-
Project 2 (Re-directing the sensitivity of metastatic castration-resistant prostate cancer to immunotherapy)
9/1/21 → 7/31/26
Project: Research project
-
SPORE in Prostate Cancer
Abdulkadir, S. A., Hussain, M., Catalona, W. J., Chakravarti, D., Kim, K. A., Morgans, A. K., Murphy, A. B., Schiltz, G. E., Wei, J., Yu, J., Kocherginsky, M., Leikin, R. G., Sosman, J. A., Wu, J. D., Yang, X. J. & Zhao, C.
9/1/21 → 7/31/26
Project: Research project
-
-
-
Correction: Inflammatory bowel disease induces inflammatory and preneoplastic changes in the prostate (Prostate Cancer and Prostatic Diseases, (2021), 10.1038/s41391-021-00392-7)
Desai, A. S., Sagar, V., Lysy, B., Weiner, A. B., Ko, O. S., Driscoll, C., Rodriguez, Y., Vatapalli, R., Unno, K., Han, H., Cohen, J. E., Vo, A. X., Pham, M., Shin, M., Jain-Poster, K., Ross, J., Morency, E. G., Meyers, T. J., Witte, J. S., Wu, J., & 2 others, Feb 2022, In: Prostate Cancer and Prostatic Diseases. 25, 2, p. 375 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostate
Desai, A. S., Sagar, V., Lysy, B., Weiner, A. B., Ko, O. S., Driscoll, C., Rodriguez, Y., Vatapalli, R., Unno, K., Han, H., Cohen, J. E., Vo, A. X., Pham, M., Shin, M., Jain-Poster, K., Ross, J., Morency, E. G., Meyers, T. J., Witte, J. S., Wu, J., & 2 others, Sep 2022, In: Prostate Cancer and Prostatic Diseases. 25, 3, p. 463-471 9 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?
Wu, J., 2021, In: Critical reviews in immunology. 41, 2, p. 101-106 6 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Direct N-Glycosylation Profiling of Urine and Prostatic Fluid Glycoproteins and Extracellular Vesicles
Blaschke, C. R. K., Hartig, J. P., Grimsley, G., Liu, L., Semmes, O. J., Wu, J. D., Ippolito, J. E., Hughes-Halbert, C., Nyalwidhe, J. O. & Drake, R. R., Sep 27 2021, In: Frontiers in Chemistry. 9, 734280.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Glioblastoma as an age-related neurological disorder in adults
Kim, M., Ladomersky, E., Mozny, A., Kocherginsky, M., O'shea, K., Reinstein, Z. Z., Zhai, L., Bell, A., Lauing, K. L., Bollu, L., Rabin, E., Dixit, K., Kumthekar, P., Platanias, L. C., Hou, L., Zheng, Y., Wu, J., Zhang, B., Hrachova, M., Merrill, S. A., & 10 others, Jan 1 2021, In: Neuro-Oncology Advances. 3, 1, vdab125.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations
Datasets
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
Zhang, J. (Creator), Larrocha, P. S. (Creator), Zhang, B. (Creator), Wainwright, D. (Creator), Dhar, P. (Contributor) & Wu, J. D. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4643378.v1, https://springernature.figshare.com/collections/Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_provides_dual_co-stimulation_of_CD8_T_cells_and_enables_sMIC_tumors_respond_to_PD1_PD-L1_blockade_therapy/4643378/1
Dataset
-
Additional file 1: of Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
Zhang, J. (Creator), Larrocha, P. S. (Creator), Zhang, B. (Creator), Wainwright, D. (Creator), Dhar, P. (Contributor) & Wu, J. D. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.9730352.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_provides_dual_co-stimulation_of_CD8_T_cells_and_enables_sMIC_tumors_respond_to_PD1_PD-L1_blockade_therapy/9730352/1
Dataset
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Contributor), Dhar, P. (Contributor), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. A. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.c.5014769.v1, https://springernature.figshare.com/collections/Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/5014769/1
Dataset
-
Additional file of Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Contributor), Dhar, P. (Contributor), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. A. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.12872204.v1, https://springernature.figshare.com/articles/dataset/Additional_file_of_Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/12872204/1
Dataset
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Contributor), Dhar, P. (Contributor), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. A. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.c.5014769.v2, https://springernature.figshare.com/collections/Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/5014769/2
Dataset